Business Context and Reporting Period
Tenaya Therapeutics, Inc. (TNYA) filed a Current Report on Form 8-K dated May 27, 2026, regarding the conclusion of its Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved the Amended and Restated 2021 Equity Incentive Plan. Key changes include a one-time increase of approximately 3% of outstanding shares (6,509,966 shares) reserved for issuance and the removal of the 4 million share annual limit on the "evergreen" provision, while maintaining a 4% annual increase based on outstanding shares.
- Director Elections: Three Class II director nominees were elected to serve until the 2029 annual meeting: Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen.
- Accounting Firm Ratification: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results and Management Commentary
The filing details the voting outcomes for three proposals:
- Proposal 1 (Directors): All three nominees received significant support, with "For" votes ranging from approximately 86.2 million to 87.3 million. Broker non-votes totaled 48,606,132 for each nominee.
- Proposal 2 (Auditor Ratification): Received 135,650,321 "For" votes against 2,023,657 "Against" votes and 1,220,906 abstentions.
- Proposal 3 (Equity Plan): Received 67,356,607 "For" votes, 20,575,701 "Against" votes, and 2,356,444 abstentions. Broker non-votes were 48,606,132.
Management commentary is limited to the description of the equity plan amendments and the incorporation by reference of the definitive proxy statement filed on April 16, 2026.
Investor Verification Checklist
- Verify the total number of outstanding shares to calculate the exact impact of the 6,509,966 share increase and the 4% annual evergreen provision.
- Review the full text of the Amended and Restated 2021 Equity Incentive Plan (Exhibit 10.1) for specific limitations on incentive stock options.
- Confirm the terms of the newly ratified engagement with Deloitte & Touche LLP for the 2026 fiscal year.
- Check subsequent filings for any financial updates, as this 8-K contains no financial performance data.